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Exposure to radiation can damage endothelial cells in the irradiated area via the production of reactive
oxygen species. We synthesized phosphine–borane complexes that reduce disulﬁde bonds and had
previously been shown to interfere with redox-mediated signaling of cell death. We hypothesized that
this class of drugs could interfere with the downstream effects of oxidative stress after irradiation and
rescue endothelial cells from radiation damage. Cultured bovine aortic endothelial cells were plated for
clonogenic assay prior to exposure to varying doses of irradiation from a 137Cs irradiator and treated with
various concentrations of bis(3-propionic acid methyl ester)phenylphosphine borane complex (PB1) at
different time points. The clone-forming ability of the irradiated cells was assessed seven days after
irradiation. We compared the radioprotective effects of PB1 with the aminothiol radioprotectant WR1065
and known superoxide scavengers. PB1 signiﬁcantly protected bovine aortic endothelial cells from ra-
diation damage, particularly when treated both before and after radiation. The radioprotection with 1 mM
PB1 corresponded to a dose-reduction factor of 1.24. Radioprotection by PB1 was comparable to the
aminothiol WR1065, but was signiﬁcantly less toxic and required much lower concentrations of drug
(1 mM vs. 4 mM, respectively). Superoxide scavengers were not radioprotective in this paradigm, in-
dicating the mechanisms for both loss of clonogenicity and PB1 radioprotection are independent of
superoxide signaling. These data demonstrate that PB1 is an effective redox-active radioprotectant for
endothelial cells in vitro, and is radioprotective at a concentration approximately 4 orders of magnitude
lower than the aminothiol WR1065 with less toxicity.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Tissue damage following ionizing radiation injuries occurs via
multiple mechanisms, including damage to endothelial cells [1–3].
Irradiated intestine [4], kidney [5], lung [6], brain [7,8], and optic
nerve [9] exhibit decreased numbers or abnormal morphology of
endothelial cells. Among the changes noted in endothelial cells
following irradiation are reductions in extracellular matrixB.V. This is an open access article u
ter)phenylphosphine borane
lphosphine borane complex;
oxide dismutase–poly-
manganese(III) tetrakis(1-
ecies; BAEC, bovine aortic
gy and Visual Sciences, Uni-
Avenue, Room 694, Madison,proteins, changes in adhesion and binding, and loss of integrity at
tight cell junctions [10]. This damage can lead to capillary rupture
or loss of small vessels. Other late effects on vessels include ab-
normal endothelial proliferation and ﬁbrosis [1]. In neuronal tis-
sues, this damage results in a disruption of the blood–brain barrier
[11]. Pulmonary tissue undergoes a similar disruption of the
blood–alveolus barrier subsequent to endothelial cell damage [12].
The effects of radiation-dependent endothelial cell injury cause
tissue-speciﬁc pathophysiology. For example, radiation to optic
nerve endothelial cells causes radiation optic neuropathies, while
that to retinal endothelial cells causes radiation retinopathy. These
diseases can lead to blindness, and are frequently seen in patients
receiving radiation treatment for ocular tumors.
Ionizing radiation acts on multiple targets within the cell. Io-
nizing radiation leads to damage of DNA bases and strand breaks,
as well as the generation of radical nucleic acids and reactive
oxygen species (ROS), including hydroxyl and superoxide ionsnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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juries makes pharmacological radioprotection an elusive goal. One
common approach is to try to minimize the effects of ROS, which
can comprise as much as 70% of the damage from irradiation, by
the addition of supplemental antioxidants in order to minimize
indirect damage to macromolecules.
Over the past two decades it has become clear that ROS are not
only chemically reactive, but act as signal transduction agents,
transducing intracellular signals via several mechanisms. Protein
targets for ROS transduction most commonly have a redox-sensi-
tive moiety, often a cysteine sulfhydryl, at the active site. Proteins
can also be covalently modiﬁed by ROS, e.g. S-nitrosylation with
NOþ , S-nitration with peroxynitrite, or glutathiolation with glu-
tathione. Redox modulation of vicinal cysteine sulfhydryls is an
efﬁcient means of modulating protein function, because the oxi-
dative cross-linking results in a disulﬁde bond that can dramati-
cally change the conformation of the active site [14,15]. Some
targets for ROS-mediated cysteine oxidation are involved in the
induction of apoptosis, e.g. creatine kinase and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) [16].
Approaches for counteracting ROS ﬁt into three categories:
prevention of ROS formation, scavenging of ROS, and reversal of
oxidative damage. ROS-mediated cell death can be prevented by
decreasing their formation from molecular oxygen [17,18], an ex-
ample of preventing the oxidation before it can occur. The lim-
itation of this approach is that the inhibitors of formation must be
present before the generation of ROS. Cells maintain a wide range
of natural systems to reduce levels of free radical species in vivo,
including catalase (H2O2), superoxide dismutase (SOD)-1, -2, -3
(superoxide), and glutathione peroxidases (R-OOH). Both upregu-
lation [19] and addition of exogenous scavengers [20] have been
shown to protect cells from radiation-induced oxidative damage.
Again, the effectiveness of this approach is dependent on the
presence of the scavengers at the time of ROS generation. The third
approach, the reversal of oxidative damage, is perhaps the most
promising of the three. As described above, ROS may induce cy-
steine modiﬁcation to elicit changes in protein conformation and
function [14,15]. Chemical reduction of the cross-linked sulfhydryl
residues can counteract and reverse the oxidative damage before
cell death signals are transduced. Of the three approaches, meth-
ods like chemical reduction of oxidized moieties have the greatest
window of opportunity for radiomitigation because they would be
effective when given before, during, or soon after oxidative injury.
Many compounds that protect against the damages of radiation
are antioxidants [21]. Thiol-containing molecules were ﬁrst found
to be effective radioprotectants in vivo in 1949, when cysteine was
used to protect mice from X-ray irradiation [22]. Further studies
demonstrated similar protective effects with other compounds
containing sulfhydryl groups, including glutathione and β-mer-
captoethylamine. These studies were performed in mice under-
going irradiation and exposed to elevated oxygen levels. Mice
exposed to elevated oxygen levels at or within 2 h after irradiation
showed increased toxicity, establishing a link between the anti-
oxidant characteristics of thiols and radioprotection [23]. Cur-
rently, the only FDA-approved radioprotectant antioxidant is the
phosphothioate amifostine [24]. Upon reaching the cell surface,
amifostine is converted by alkaline phosphatase to its active, free
thiol form, or WR1065.
The mechanism by which thiols are radioprotective is still not
completely understood. Hypothesized pathways include direct
scavenging of free radicals [25], reduction of disulﬁde bonds [26],
and activation of transcription factors driving cytoprotective gene
expression [19]. It is possible that a combination of these actions is
responsible for the observed protection from radiation. However,
these drugs are radioprotective, not radiomitigative, and have
signiﬁcant systemic toxicity.We have developed a class of new chemical entities that are
able to interfere with downstream effects of ROS. Novel sulfhydryl
reducing agents bis(3-propionic acid methyl ester)phenylpho-
sphine borane complex (PB1) and (3-propionic acid methyl ester)
diphenylphosphine borane complex (PB2) are able to protect ret-
inal ganglion cells against apoptosis following axonal injury, a
superoxide-dependent process [27], without direct scavenging of
superoxide. These phosphines are alternatives to thiol drugs, and
are structurally similar to the reducing agent tris(2-carboxyethyl)
phosphine (TCEP), which is neuroprotective for retinal ganglion
cells [17,28] and photoreceptors [29]. PB1 and PB2 were designed
to have low reactivity in the extracellular compartment, high rates
of transmembrane diffusion, and a side-group that can be cleaved
by intracellular enzymes, resulting in an intracellular accumula-
tion of PB1 or PB2. PB1 and PB2 are neuroprotective in vitro in
axotomized primary retinal ganglion cells [27] and a neuronal cell
line where the mitochondrial electron transport chain compo-
nents are inhibited [30]. They are also neuroprotective in vivo in
rat optic nerve crush and ocular hypertension models [31].
Given that axotomy-induced superoxide-dependent retinal
ganglion cell apoptosis is decreased by treatment with the redu-
cing agent PB1 and that irradiation-induced endothelial cell death
is decreased through treatment with antioxidants and thiol-based
compounds, we hypothesized that treatment with PB1 would re-
duce clonogenic death in endothelial cells exposed to ionizing
radiation. PB1 was radioprotective of endothelial cells to a similar
degree as WR1065 but at much lower effective concentrations and
without the associated toxicity that limits the use of WR1065.
Unlike WR1065, PB1 was also protective against direct oxidative
stress with t-butyl hydroperoxide and showed some evidence of
radiomitigative effects.2. Materials and methods
2.1. Chemicals
The aminothiol WR1065 and superoxide dismutase–poly-
ethylene glycol from bovine erythrocytes (PEG-SOD) were from
Sigma-Aldrich (St. Louis, MO). Manganese(III) tetrakis(1-methyl-4-
pyridyl)porphyrin (MnTMPyP) was from Adipogen (San Diego, CA).
Hydroethidine (HEt) was from Anaspec Solutions (Waddinxveen
Zuid-Holland, Netherlands). Phenylphosphine was from Strem
Chemicals Inc. All other chemicals and solvents were from Sigma-
Aldrich (Milwaukee, WI).
2.2. Synthesis of bis(3-propionic acid methyl ester)phenylphosphine
borane complex (PB1)
To a ﬂame-dried round bottom ﬂask ﬁtted with magnetic stir-
bar was added phenylphosphine (5.00 ml, 45.0 mmol) to degassed
acetonitrile (5.00 ml) under argon atmosphere. The solution was
cooled to 0 °C and methyl acrylate (8.10 ml, 90 mmol) was added
slowly drop-wise. After complete addition of methyl acrylate, the
solution was warmed to room temperature, and stirred overnight.
After 19 h, the solvent was removed in vacuo and dry tetra-
hydrofuran was added (15 ml). The solution was placed under ar-
gon, cooled to 0 °C and borane-dimethylsulﬁde (4.5 ml,
45.0 mmol) was added slowly drop-wise. The reaction was
warmed to room temperature to stir for 45 min. The solvent was
removed in vacuo and the crude product was puriﬁed by ﬂash
chromatography (silica gel, gradient elution 10–20% EtOAc in
hexanes). Phosphine–borane complex 1 (PB1) was isolated as a
clear oil (7.83 g, 26.4 mmol, 58% yield over two steps).
Reactions were monitored by thin-layer chromatography and
visualized by ultraviolet light or staining with I2. 1H and 13C NMR
Fig. 1. Radiation exposure leads to a decrease in colony-forming potential of BAEC.
Cells were assayed for clonogenic activity following exposure to 0–6 Gy of ionizing
radiation and exhibited a near-linear decrease in colony-forming capacity with
increasing radiation. Results are from 12 independent experiments, and are pre-
sented as mean7SEM.
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using CDCl3 with TMS or residual solvent as standard unless
otherwise noted. Low-resolution mass spectra were obtained
using an Agilent 1100 series LS/MSD using atmospheric pressure
chemical ionization (APCI).
PB1: Rf¼0.30 [33% EtOAc in hexanes]; 1H NMR (400 MHz,
CDCl3) δ 0.67 (d, J¼122.7 Hz, 3H), 2.14–2.39 (m, 6H), 2.53–2.69 (m,
2H), 3.63 (d, J¼0.7 Hz, 6H), 7.43–7.60 (m, 3H), 7.67–7.78 (m, 2H);
13C NMR (126 MHz, CDCl3) δ 21.06 (d, J¼38.3 Hz), 27.67 (d,
J¼1.6 Hz), 52.13, 126.41 (d, J¼52.0 Hz),129.22 (d, J¼9.7 Hz), 132.10
(d, J¼2.4 Hz), 132.20 (d, J¼9.2 Hz), 172.61 (d, J¼15.6 Hz). 31P NMR
(162 MHz, CDCl3) δ 17.85 (d, J¼70.0 Hz); mass spectrum (APCI) m/
e 295.1 (65) (M–H)þ , 283.2 (100) (M–BH2)þ .
2.3. Cell culture
Bovine aortic endothelial cells (BAEC) were purchased from Cell
Applications, Inc. (San Diego, CA) and harvested up to passage 9.
Cells were grown at 37 °C in 5% CO2 on tissue-culture ﬂasks in
bovine EC basal medium supplemented with 10% bovine EC
growth supplement, both from Cell Applications, Inc.
2.4. Irradiation
Before treatment, BAEC were plated on 6-well plates at 100
cells per well. After 24 h in culture, all plates were removed from
the incubator for the duration of irradiation treatment. Treatment
conditions received single doses of radiation between 1 and 6 Gy
using a 137Cs irradiator (JL Shepherd & Associates; San Fernando,
CA) delivering radiation at a rate of 4.3905 Gy per minute. PB1 was
administered 24 and 2 h before, at the time of, and/or 24, 48, 72,
and 120 h after irradiation. It was also administered 2 h before
irradiation and removed immediately after irradiation. WR1065
was administered 2 h before irradiation and removed immediately
after as a positive control. In some experiments, WR1065 was al-
lowed to remain in the medium to assess toxicity.
2.5. Clonogenic assays
Cells were grown in 6-well tissue culture plates at a density of
approximately 100 cells/well, and treated in sextuplicate. Cell
viability was assessed by measuring cells’ ability to propagate via
clonogenic assay, i.e. clonogenicity [32]. A week after irradiation,
media was removed and the wells rinsed with 1 PBS. Cells were
ﬁxed with 6% glutaraldehyde and stained with 0.5% crystal violet
solution. Thirty minutes later, the crystal violet solution was re-
moved and the wells rinsed with water. Blue-staining colonies (1–
5 mm in diameter) were manually counted and results tabulated.
Plating efﬁciency of non-irradiated, untreated controls ranged
from 20-57% and all clone counts were normalized to that condi-
tion within each experiment for comparison across repetitions.
Rescue of clonogenicity was calculated by determining the number
of colonies in treated cells compared to irradiated controls as a
fraction of the number of colonies in non-irradiated cells com-
pared to irradiated controls, i.e.
C C
C C
.tx irr
nonirr irr
−
−
2.6. Assessment of intracellular superoxide levels
Levels of intracellular superoxide were assessed using dihy-
droethidium (HEt), which is converted to ﬂuorescent 2-hydro-
xyethidium in the presence of superoxide [33]. In order to test
whether ionizing radiation results in an increase in intracellularsuperoxide, cells were plated in black 96-well plates (Corning,
Tewksbury, MA) at a density of 2000 cells per well 24 h prior to
irradiation. Cells were treated with 3.2 mM HEt in medium 30 min
before irradiation, followed by received single doses of radiation
between 0 and 6 Gy. Fluorescence was assessed 5 min after irra-
diation using a 1420 Victor 2 T Multilabel Counter (excitation
485 nm, emission 580 nm). After subtracting background ﬂuores-
cence seen in medium-only wells, ﬂuorescence readings were
compared among cells not subjected to radiation, irradiated cells,
and irradiated cells treated with PEG-SOD (0.3–30 U/ml). Condi-
tions were performed in sextuplicate.
2.7. Statistics
Comparisons between groups were by unpaired t-test. The
clonogenic rescue percentages were used for comparison in order
to minimize between-experiment variability in radiation response
in untreated cells. All results are presented as mean7SEM.3. Results
3.1. PB1 is radioprotective for bovine aortic endothelial cells
Cultured BAEC were exposed to irradiation ranging from 1 Gy
to 6 Gy and their ability to divide was measured by clonogenic
assay, with colony counts performed seven days later. There was a
near-linear toxicity associated with increasing doses of radiation,
with colony-forming potential (as a percentage of non-irradiated
cells) ranging from 84.3%72.7% with 1 Gy to 7.1%70.8% with 6 Gy
(po0.001 for all comparisons; Fig. 1).
To assess radioprotection with PB1 (Fig. 2A), cultured BAEC
were exposed to irradiation in the presence of varying con-
centrations of PB1. A single dose of 3 Gy irradiation resulted in a
64.4%72.2% reduction in colony formation compared to non-ir-
radiated cells seven days after irradiation. Treatment with 10 nM,
100 nM, 1 mM, or 10 mM PB1 at the time of irradiation resulted in a
signiﬁcant dose-dependent improvement in colony formulation
(Fig. 2B), with corresponding radioprotective rescue of 15.4%
74.2%, 11.1%74.0%, 21.5%73.5%, and 20.3%74.9% (p¼0.002,
0.02, o0.001, and o0.001 respectively). Treatment with PB1 2 h
prior to irradiation also conferred signiﬁcant protection to colony
formation (Fig. 2C), with corresponding radioprotective rescue
values of 15.7%74.7%, 21.4%74.1%, 22.4%73.3%, and 26.6%74.8%
for 10 nM through 10 mM PB1 respectively (po0.01). The
Fig. 2. PB1 is radioprotective for BAEC. (A) Chemical structure of bis(3-propionic acid methyl ester)phenylphosphine borane complex (PB1). (B) PB1 (10 nM to 10 mM) was
administered to cultured cells at the time of irradiation (3 Gy). Treatment resulted in signiﬁcant recovery of colony-forming potential of the cells in a dose-dependent
fashion. Asterisks represent values signiﬁcantly (po0.02) different from untreated, irradiated cells. (C) PB1 (10 nM to 10 mM) was administered to cultured cells 2 h prior to
irradiation (3 Gy). Treatment resulted in signiﬁcant recovery of colony-forming potential of the cells in a dose-dependent fashion. Asterisks represent values signiﬁcantly
(po0.01) different from untreated, irradiated cells. Results are from 8 (panel B) or 5 (panel C) independent experiments, and are presented as mean7SEM.
M.E. Crowe et al. / Redox Biology 6 (2015) 73–7976radioprotection with 1 mM PB1 when administered 2 h prior to
irradiation corresponded to a dose-reduction factor of 1.24.
3.2. PB1 is signiﬁcantly less toxic than WR1065
WR1065 is a thiol-based radioprotectant that is the effector
molecule for amifostine, the only FDA-approved radioprotectant.
The radioprotective activities of PB1 and WR1065 were compared.
BAEC were treated with PB1 or WR1065 2 h before 3 Gy irradiation
and the cells incubated for a further 7 days in the presence of
radioprotectant. There was signiﬁcant radioprotection with PB1
but no colonies were seen with WR1065 (Fig. 3; middle bars).
However, when drugs were removed immediately after irradia-
tion, both PB1 and WR1065 were radioprotective (Fig. 3; rightmost
bars). These data indicate that although WR1065 was radio-
protective, it was toxic to cells when present for 7 days. PB1, on the
other hand, retained its radioprotective qualities and had minimal
toxicity when incubated with cells for 7 days.
3.3. Time course of PB1-mediated radioprotection
To assess the effectiveness of PB1 as both a radiomitigator and a
radioprotector, PB1 (ﬁnal concentration 1 mM) was added to BAEC100
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Fig. 3. PB1 is less toxic than WR1065. WR1065, the effector molecule of the
radioprotective pro-drug amifostine (4 mM), was compared to PB1 (1 mM). PB1
signiﬁcantly restored colony-forming potential when not removed following irra-
diation, while WR1065 resulted in complete toxicity (0 surviving colonies). When
treatments were removed immediately following irradiation, WR1065 and PB1
showed comparable levels of protection. Asterisks represent values signiﬁcantly
(po0.02) different from untreated, irradiated cells. Results are from 2 independent
experiments, and are presented as mean7SEM.cultures at various time points before and after irradiation.
Treatment after irradiation at either þ24 h or þ24, 48, 72, and
120 h resulted in statistically insigniﬁcant rescue of clonogenicity
of 4.9%76.1% and 6.7%75.5% (Fig. 4). Treatment before irradiation
at either 2 h or 24 h and 2 h resulted in greater radio-
protective rescue (15.6%74.9% and 11.9%75.2%; p¼0.02). Opti-
mal radioprotection was seen with PB1 when added both before
and after irradiation, at 24, 2, þ24, þ48, þ72 and þ120 h,
with radioprotective rescue of 23.8%77.0% (p¼0.008). In sum-
mary, treatment with PB1 before and after irradiation was more
effective than at either time alone.3.4. PB1 radioprotection is independent or downstream of irradia-
tion-induced superoxide
3.4.1. Irradiation of BAEC results in an increase in intracellular su-
peroxide levels
We had previously shown that PB1 interferes with retinalFig. 4. Time course of PB1-mediated radioprotection. PB1 (1 mM) was added at
various times ranging from 24 h before to 120 h after radiation to investigate the
potential for PB1 as a radiomitigant. While PB1 did not confer signiﬁcant protection
when added only following irradiation, multiple additions before and after ex-
posure resulted in signiﬁcant recovery of colony formation. Asterisk represents a
value signiﬁcantly (po0.02) different from untreated, irradiated cells. Results are
from 2 independent experiments, and are presented as mean7SEM.
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Fig. 5. Radiation induces superoxide in BAEC. BAEC were irradiated (0, 2, 4, or 6 Gy)
after loading with a superoxide-sensitive ﬂuorescent marker. Increasing radiation
doses led to higher ﬂuorescence levels, which were signiﬁcantly reduced in the
presence of PEG-SOD. Results shown are from a single representative experiment.
Asterisks represent values signiﬁcantly (po0.05) different from irradiated cells in
the absence of PEG-SOD. Results are from 3 independent experiments, and are
presented as mean7SEM.
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(2 Gy) in the presence or absence of the SOD mimetic MnTMPyP (25 mM) or PEG-
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Fig. 7. PB1 protects BAEC from induced oxidative stress. Direct oxidative stress was
induced in BAEC through addition of tBHP (0, 100, 316 or 1000 nM). Treatment with
PB1 (1 mM) signiﬁcantly ameliorated the loss in colony-forming potential at all
tested levels of oxidative stress. Asterisks represent values signiﬁcantly (po0.001)
different from tBHP-treated cells in the absence of pharmacological treatment.
Results are from 2 independent experiments, and are presented as mean7SEM.
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by superoxide [35–37]. In order to determine whether irradiation-
induced cell death was associated with generation of superoxide,
hydroethidine (HEt) was used measure intracellular superoxide
levels following irradiation. Single doses of irradiation (2 Gy, 4 Gy,
or 6 Gy) resulted in a dose-dependent increase in ﬂuorescence
readings (Fig. 5), indicating higher levels of superoxide, compared
to non-irradiated cells (p¼0.13, po0.001, po0.001, respectively).
Treatment with 0.3, 3, and 30 U/ml PEG-SOD, a superoxide sca-
venger, before 4 Gy or 6 Gy irradiation resulted in signiﬁcantly
lower HEt ﬂuorescence levels than those seen in irradiated cells
without PEG-SOD.
3.4.2. Superoxide scavenging is not radioprotective for bovine aortic
endothelial cells
Given that irradiation of BAEC increased intracellular levels of
superoxide and WR1065 induces MnSOD expression [19], experi-
ments were performed to see if modulating superoxide levels
improved their survival. BAEC were treated with the known su-
peroxide scavengers PEG-SOD and MnTMPyP, followed by irra-
diation and clonogenic assay 7 days later. Neither scavenger was
signiﬁcantly radioprotective, determined by clonogenic assay of
irradiated cells (Fig. 6). Irradiation with 2 Gy was used to increase
the likelihood of detecting a small effect on clonogenic potential.
Treatment with PEG-SOD minimally affected the clonogenic po-
tential of irradiated cells, increasing slightly from 73.2%73.3% to
75.3%76.2 (p¼NS). Similar results were seen when cells were
irradiated with 3 Gy. Treatment with a different superoxide dis-
mutase mimetic, MnTMPyP, resulted in toxicity to cells in all
conditions. Therefore, reducing superoxide levels in these cells
was not radioprotective.
3.4.3. PB1 protects from induced oxidative stress
PB1 is a redox-active disulﬁde reducing agent. Given that PB1
was radioprotective but does not scavenge superoxide [30], we
hypothesized that it would protect against oxidative damage not
directly associated with superoxide. We assessed this by testing
whether PB1 could rescue endothelial cells from direct oxidative
damage. BAEC were treated with tert-butyl hydroperoxide (tBHP)
at concentrations from 100 nM to 1 mM for 24 h in the presence or
absence of 1 mM PB1. Oxidative damage mediated by 100 nM,
316 nM, and 1 mM tBHP resulted in decreased clonogenic potentialthat was dose-dependent (Fig. 7). Treatment with 1 mM PB1 sig-
niﬁcantly rescued lost clonogenic potential at all concentrations of
tBHP, rescuing 46.7%78.8%, 50.1%77.3%, and 32.9%74.3% of
clones respectively (po0.001). WR1065 (4 mM) showed non-
signiﬁcant protection from tBHP at all doses. These data indicate
that radioprotection by PB1 is independent or downstream of an
irradiation-induced oxidative signal.4. Discussion
These data demonstrate that the novel reducing agent bis(3-
propionic acid methyl ester)phenylphosphine borane complex
(PB1) is an effective radioprotectant for endothelial cells in vitro.
PB1 restored clonogenicity to an equal or greater degree than the
clinical radioprotectant WR1065 at a concentration approximately
4 orders of magnitude lower and without any of the observed
toxicity [38] that has limited the clinical applications of the pro-
drug for WR1065, amifostine. Although radiation induced
M.E. Crowe et al. / Redox Biology 6 (2015) 73–7978generation of superoxide in these cells, dismutation of superoxide
anion was not radioprotective. Finally, treatment with PB1 after
irradiation had a small positive effect on clonogenicity, suggesting
a potential role for this class of drugs as a radiomitigant.
Irradiation-induced endothelial damage is a limiting factor for
radiation dosing in radiation therapy. In the treatment of ocular,
orbital, or intracranial tumors, for example, exposure to ther-
apeutic irradiation may result in delayed and irreversible loss of
vision due to radiation optic neuropathy [39]. Clinically, there is
subacute visual loss occurring months to years after irradiation,
with radiographic evidence of breakdown of the blood-nerve
barrier [40]. The mechanism responsible for these features is not
known, but endothelial cell damage is a consistent ﬁnding. Similar
ﬁndings have been reported in a variety of other healthy tissues
following irradiation [4–7]. The development of an endothelial
radioprotectant would allow for more aggressive treatment of
tumors while minimizing off-target effects.
The mechanism by which PB1 is radioprotective is unlikely to
be related to superoxide scavenging, given that superoxide
scavenging in these cells is not radioprotective and PB1 does not
scavenge superoxide [30]. The radioprotective mechanism is more
likely related to its phosphine group, which has functionality that
parallels those of thiols. The active thiol (WR1065) and disulﬁde
(WR33278) forms of amifostine are radioprotective via a variety of
mechanisms [41]. WR1065 and WR33278 are positively-charged
polyamines similar in structure to spermine. They localize to the
nucleus where they associate with DNA as a positively charged
counterion to negatively charged phosphates [42,43], modulate
the cell cycle and DNA repair through regulation of a host of genes,
and act to stabilize DNA while scavenging hydroxyl and DNA ra-
dicals. The effectiveness of various thiols as radioprotectants
in vivo corresponds directly to their charge, suggesting that loca-
lization to negatively-charged organelles (e.g. nuclei and mi-
tochondria) plays a role in their radioprotective capacity [44].
In contrast, PB1 undergoes reduction to a negatively-charged
diacid, which would not be expected to localize to negatively-
charged organelles. In fact, we observed that PB1 has a greater
capacity for protection against ROS generated outside the mi-
tochondrial matrix than inside [30], suggesting that charge affects
subcellular localization of PB1.
Thiols chelate a variety of metals and in some cases remove
metal cofactors from enzymes [45]. This is an unlikely mechanism
for PB1. Phosphines vary greatly in their ability to chelate metals at
biological pH levels, depending on their electronic and steric
properties. The diacid metabolite of PB1 is similar to TCEP, which is
a fairly weak metal chelator [46]. Therefore, PB1 would be unlikely
to compete with metal cofactors at the low concentrations used in
our study.
The most likely mechanism for PB1-mediated radioprotection
relates to effects on cellular redox state, which is affected both by
thiols and phosphines. Modulation of redox state can result in
signal transduction, gene induction, and chemical reduction of
oxidized protein disulﬁdes. While a number of redox-sensitive
transcription factors are possible targets (p53, NF-kB, AP-1, Nrf2)
[47–49], the ability of PB1 to confer a high degree of protection at a
micromolar dose suggests either high speciﬁcity of PB1 for an ef-
fector molecule or mediation by an alternate pathway.
Although PB1 is effective against irradiation in healthy en-
dothelial cells in vitro, it is unknown how well it would function in
the milieu of tumor cells or in vivo. Identiﬁcation of the targets for
reduction is crucial for medicinal chemistry optimization of PB1
for radioprotection, with goals of diminishing off-target effects,
and increasing efﬁcacy. It may be possible to achieve subcellular
localization and targeting of compounds based on PB1 with ap-
propriate choices of substituted side chains and charged functional
groups. We are currently investigating the effect of different sidechains as a means of optimizing organelle afﬁnity for phosphine–
borane complexes. The ideal compound would be highly radio-
protective for normal but not tumor cells.
In addition to radiotherapeutic use, the potential for phos-
phine–borane complexes to act as radiomitigants creates a win-
dow for treating acute radiation toxicity due to unanticipated ex-
posure to high levels of ionizing radiation, e.g. terrorism or acci-
dents. When exposure cannot be predicted in advance, it is only
through blocking or reversal of downstream cell-death signaling
pathways that protection can be achieved, limiting the usefulness
of compounds which function only as radioprotectants. The
modest amount of radiomitigative activity seen with PB1 would
require optimization in order for it to be suitable for treatment of
acute radiation toxicity.Acknowledgments
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